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2007-2008 Influenza Season 
Week 16, ending April 19, 2008 
 (All data are preliminary and may change as more reports are received.) 
 
Synopsis:  During week 16 (April 13 – 19, 2008), influenza activity continued to decrease in the 
United States.   
o One hundred ninety (9.2%) specimens tested by U.S. World Health Organization (WHO) 
and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating 
laboratories were positive for influenza. 
o The proportion of deaths attributed to pneumonia and influenza has been above the 
epidemic threshold for 15 consecutive weeks. 
o The proportion of outpatient visits for influenza-like illness (ILI) and acute respiratory illness 
(ARI) was below national and region-specific baseline levels.   
o One state reported widespread influenza activity; four states reported regional influenza 
activity; 14 states reported local influenza activity; 29 states and the District of Columbia 
reported sporadic influenza activity; one state reported no influenza activity; and one state 
did not report. 
 
National and Regional Summary of Select Surveillance Components 
  Data for current week Data cumulative for the season 
  
Sentinel 
Provider 
ILI* 
DoD and 
VA ARI* 
% pos. 
for flu†
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity‡  
A 
(H1) 
A 
(H3) 
A 
Unsub
-typed 
B Pediatric Deaths 
Nation Normal Normal 9.2% 5 of 51  2164 5994 18587 10006 68 
New 
England Normal Normal 13.5% 2 of 6 95 210 981 1002 8 
Mid-
Atlantic Normal Normal 16.9% 3 of 3 209 350 1190 1361 12 
East North 
Central Normal Normal 12.9% 0 of 5 185 1413 627 560 8 
West 
North 
Central Normal Normal 16.4% 0 of 7 106 236 3023 1703 6 
South 
Atlantic Normal Normal 10.1% 0 of 9 351 1822 4724 1640 7 
East 
South 
Central Normal Normal 14.6% 0 of 4 37 758 145 144 6 
West South 
Central Normal Normal 5.3% 0 of 4 109 497 5988 1711 8 
Mountain Normal Normal 10.2% 0 of 8 530 469 999 1075 6 
Pacific Normal Normal 12.5% 0 of 5 542 239 910 810 7 
* Elevated means the % of visits for ILI or ARI is at or above the national or region-specific baseline 
† National data are for current week; regional data are for the most recent three weeks 
‡ Includes all 50 states and the District of Columbia 
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Laboratory Surveillance:  During week 16, WHO and NREVSS laboratories reported 2,070 
specimens tested for influenza viruses, 190 (9.2%) of which were positive, including 14 influenza A 
(H3) viruses, 49 influenza A viruses that were not subtyped, and 127 influenza B viruses.   
 
Since September 30, 2007, WHO and NREVSS laboratories have tested a total of 199,321 
specimens for influenza viruses and 36,751 (18.4%) were positive. Among the 36,751 influenza 
viruses, 26,745 (72.8%) were influenza A viruses and 10,006 (27.2%) were influenza B viruses.  
Eight thousand one hundred fifty-eight (30.5%) of the 26,745 influenza A viruses have been 
subtyped: 2,164 (26.5%) were influenza A (H1) viruses and 5,994 (73.5%) were influenza A (H3) 
viruses. 
 
During the 2007-08 season, influenza A (H1), A (H3), and B viruses have co-circulated in the United 
States.  Influenza A (H3) viruses have predominated during the season overall, however, the most 
commonly reported influenza virus has varied by week.  From week 40 through week 3 (September 
30, 2007 – January 19, 2008) influenza A (H1) viruses were more frequently reported; from week 4 
through week 12 (January 20 – March 22, 2008), influenza A (H3) viruses were more commonly 
reported; and from weeks 13 through 16 (March 23 – April 19, 2008), more influenza B than 
influenza A viruses were reported.  The predominant virus has also varied by region.  Influenza A 
(H3) viruses have been reported more frequently than A (H1) viruses in seven of the nine 
surveillance regions (East North Central, East South Central, Mid-Atlantic, New England, South 
Atlantic, West North Central, and West South Central) while influenza A (H1) viruses have 
predominated this season in two regions (Mountain and Pacific). 
U.S. WHO/NREVSS Collaborating Laboratories
National Summary, 2007-08
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Composition of the 2008-09 Influenza Vaccine:  WHO and FDA have recommended that the 
2008-09 trivalent influenza vaccine for the Northern Hemisphere contain A/Brisbane/59/2007-like 
(H1N1), A/Brisbane/10/2007-like (H3N2), and B/Florida/4/2006-like viruses.  All three components 
have been changed from the 2007-08 Northern Hemisphere vaccine formulation.  
A/Brisbane/10/2007-like (H3N2) and B/Florida/4/2006-like viruses are currently included in the 2008 
Southern Hemisphere vaccines.  This recommendation was based on surveillance data related to 
epidemiology and antigenic characteristics, serological responses to 2007-08 vaccines, and the 
availability of candidate strains and reagents. 
2007-2008 Influenza Season – Week 16, ending April 19, 2008           
 
3
 
Antigenic Characterization:  CDC has antigenically characterized 660 influenza viruses [330 
influenza A (H1N1), 161 influenza A (H3N2), and 169 influenza B viruses] collected by U.S. 
laboratories since September 30, 2007. 
 
Influenza A (H1N1) [330] 
• Two hundred twenty (67%) of the 330 viruses were characterized as A/Solomon 
Islands/3/2006-like, the influenza A (H1N1) component of the 2007-08 influenza 
vaccine for the Northern Hemisphere and the 2008 influenza A (H1N1) component 
for the Southern Hemisphere. 
• Twenty (6%) of the 330 viruses showed somewhat reduced titers with antisera 
produced against A/Solomon Islands/3/2006. 
• Ninety (27%) of the 330 viruses were characterized as A/Brisbane/59/2007-like. 
A/Brisbane/59/2007 is a recent genetic/antigenic variant which evolved from 
A/Solomon Islands/03/2006. An A/Brisbane/59/2007-like virus is the WHO 
recommended strain for the 2008-09 Northern Hemisphere vaccine formulation. 
Influenza A (H3N2) [161] 
• Thirty-five (22%) of the 161 viruses were characterized as A/Wisconsin/67/2005-like, 
the influenza A (H3N2) component of the 2007-08 influenza vaccine for the Northern 
Hemisphere. 
• One hundred fifteen (71%) of the 161 viruses were characterized as 
A/Brisbane/10/2007-like.  A/Brisbane/10/2007-like viruses are a recent antigenic 
variant which evolved from, but are antigenically distinct from, A/Wisconsin/67/2005-
like viruses.  A/Brisbane/10/2007-like virus is the recommended influenza A (H3N2) 
component for the 2008 Southern Hemisphere and 2008-09 Northern Hemisphere 
vaccines. 
• Eleven (7%) of the 161 viruses showed somewhat reduced titers with antisera 
produced against A/Wisconsin/67/2005 and A/Brisbane/10/2007. 
 
Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [169] 
Victoria lineage [8] 
• Eight (5%) of the 169 influenza B viruses characterized belong to the B/Victoria 
lineage of viruses. 
o Six (75%) of these 8 viruses were characterized as B/Ohio/01/2005-like. The 
recommended influenza B component for the 2007-08 influenza vaccine is a 
B/Malaysia/2506/2004-like virus, belonging to the B/Victoria lineage.  
B/Ohio/01/2005 is a recent B/Malaysia/2506/2004-like reference strain. 
o Two (25%) of these 8 viruses showed somewhat reduced titers with antisera 
produced against B/Ohio/01/2005 and B/Malaysia/2506/2004.  
Yamagata lineage [161] 
• One hundred sixty-one (95%) of the 169 influenza B viruses characterized belong to 
the B/Yamagata lineage of viruses.   
o One hundred fifty-six (97%) of these 161 viruses were identified as 
B/Florida/04/2006-like, the recommended influenza B component for the 
2008-09 Northern Hemisphere vaccine formulation. 
o Five (3%) of these 161 viruses showed a somewhat reduced titer with 
antiserum produced against B/Florida/04/2006.  
 
These data indicate similarities and differences between a sample of circulating strains and this 
year's vaccine strains as determined by laboratory studies. Interim results from a study carried out 
with the Marshfield Clinic in Wisconsin found vaccine effectiveness of 58% against circulating 
influenza A (H3N2) viruses, based on data collected from Jan 21 through Feb 8, 2008. No vaccine 
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effectiveness against influenza B viruses was found.  No influenza A (H1N1) viruses were identified 
through Feb 8 and, thus, no vaccine effectiveness estimate is available for H1N1 viruses.  These 
interim results suggest that vaccination provided substantial protection against H3N2 influenza-
associated medically attended illness in the study population. Enrollment in this study concluded on 
March 28, 2008, and final results will be available later this year.  Additional information on this 
study can be found at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5715a1.htm 
 
Antiviral Resistance: In the United States, two groups of antiviral drugs have been approved by 
FDA for use in treating or preventing influenza virus infections.  These two groups of antiviral drugs 
are: neuraminidase inhibitors (oseltamivir and zanamivir) and adamantanes (amantadine and 
rimantadine). A description of these drugs can be found at: 
http://www.cdc.gov/flu/protect/antiviral/index.htm.  
 
Neuraminidase Inhibitor Antiviral Drugs:  So far this season, 1,195 influenza A and B 
viruses from the United States have been tested for antiviral resistance.  Eighty-seven 
(8.3%) of 1,048 influenza A viruses tested, and 0 (0.0%) of 147 influenza B viruses tested 
have been found to be resistant to oseltamivir.  Currently all of the resistant viruses are 
influenza A (H1N1) viruses, with 87 (10.4%) of 838 influenza A (H1N1) viruses tested 
exhibiting a genetic mutation that confers oseltamivir resistance.  All tested viruses retain 
their sensitivity to zanamivir.  Additional information on antiviral resistance can be found at: 
http://www.cdc.gov/flu/about/qa/antiviralresistance.htm 
 
Adamantane Antiviral Drugs: Resistance to the adamantanes continues to be high among 
influenza A (H3N2) viruses with 278 (99.6%) of 279 influenza A (H3N2) viruses tested 
resistant to the adamantanes.  Adamantane resistance among influenza A (H1N1) viruses 
has also been detected but at a lower level. Of 755 influenza A (H1N1) viruses tested, 83 
(11.0%) were resistant to the adamantanes.  The adamantanes are not effective against 
influenza B viruses.  Since late January, influenza A (H3N2) viruses have predominated in 
the United States, and during week 16, 100% of influenza A viruses subtyped were A 
(H3N2).  
 
Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, 
persisting high levels of resistance to the adamantanes in H3N2 viruses, and the 
predominance of H3N2 viruses circulating in the United States during the 2007-08 season 
with co-circulation of influenza B viruses, CDC continues to recommend the use of 
oseltamivir and zanamivir for the treatment or prevention of influenza.  Use of amantadine or 
rimantadine is not recommended.  Guidance on influenza antiviral use can be found at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 16, 8.2% of all deaths 
reported through the 122 Cities Mortality Reporting System were reported as due to P&I. This 
percentage is above the epidemic threshold of 6.8% for week 16.  Including week 16, P&I mortality 
has been above epidemic threshold for 15 consecutive weeks. 
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Influenza-Associated Pediatric Mortality: Two influenza-associated pediatric deaths were 
reported to CDC during week 16 (AZ (1), NH (1)).  These deaths occurred during weeks 13 – 14 
(March 23 – April 5, 2008).  Since September 30, 2007, CDC has received a total of 68 reports of 
influenza-associated pediatric deaths that occurred during the current season.   
Number of Influenza-Associated Pediatric Deaths
by Week of Death:
2005-06 season to present
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Influenza-Associated Pediatric Hospitalizations:  Laboratory-confirmed influenza-associated 
pediatric hospitalizations are monitored in two population-based surveillance networks: the New 
Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).  These two 
systems provide updates of surveillance data every two weeks.  As a result of differing dates for 
initiating surveillance in the 2007-08 season, these updates occur on alternating weeks.  
During November 4, 2007 to April 5, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate for children 0-4 years old in the NVSN was 6.78 per 10,000. 
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During September 30 – April 12, 2008, the preliminary laboratory-confirmed influenza-associated 
hospitalization rate reported by the EIP for children 0–17 years old was 1.38 per 10,000.  For 
children aged 0-4 years and 5-17 years, the rate was 3.62 per 10,000 and 0.48 per 10,000, 
respectively.  
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children Aged 0-4 and 5-17 yrs, 2007-2008 and 
Previous 4 Seasons
0
1
2
3
4
5
6
7
8
9
10
40 41 42 43 44 45 46 47 48 49 50 51 52 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Week
Po
pu
la
tio
n-
Ba
se
d 
Ra
te
 p
er
 1
0,
00
0 
Ch
ild
re
n
2003-04, 0-4 years 2003-04, 5-17 years
2004-05, 0-4 years 2004-05, 5-17 years
2005-06, 0-4 years 2005-06, 5-17 years
2006-07, 0-4 years 2006-07, 5-17 years
2007-08, 0-4 years 2007-08, 5-17 years
 
 
Outpatient Illness Surveillance:  Nationwide during week 16, 1.2% of outpatient visits reported 
through the U.S. Influenza Sentinel Provider Surveillance Network were due to influenza-like illness 
(ILI), which was below the national baseline of 2.2%.  On a regional level, the percentage of 
outpatient visits for ILI ranged from 0.7% to 2.8%.  All nine regions reported ILI below their region-
specific baselines. 
During week 16, 2.0% of patient visits to Department of Veteran’s Affairs (VA) and Department of 
Defense (DoD) outpatient treatment facilities were for acute respiratory illness (ARI), which was 
below the national baseline of 3.2%.  On a regional level, the percentage of visits for ARI ranged 
from 1.1% to 2.5%, and was below region-specific baselines in all nine regions.  All five age groups 
reported ARI below their age-specific baselines.   
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Percentage of Visits for ILI & ARI Reported
by Sentinel Providers and BioSense Outpatient Facilities,
National Summary
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Percentage of Visits for ARI by Age Group Reported by 
DoD/VA Outpatient Clinics - National Summary
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: During 
week 16 the following influenza activity was reported: 
• Widespread activity was reported by one state (New York). 
• Regional activity was reported by four states (Connecticut, New Hampshire, New Jersey, 
and Pennsylvania). 
• Local influenza activity was reported by 14 states (Alaska, Arizona, Florida, Hawaii, Idaho, 
Maine, Maryland, Massachusetts, Montana, North Dakota, Oregon, Rhode Island, South 
Carolina, and Vermont). 
• Sporadic influenza activity was reported by the District of Columbia and 29 states (Alabama, 
Arkansas, California, Colorado, Delaware, Georgia, Illinois, Indiana, Iowa, Kansas, 
Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Mexico, 
North Carolina, Ohio, Oklahoma, South Dakota, Tennessee, Texas, Utah, Virginia, West 
Virginia, Wisconsin, and Wyoming). 
• No influenza activity was reported by one state (Kentucky). 
• One state did not report (Washington). 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
Report prepared: April 25, 2008.
 
